Trading
QBiotics Group Limited
Naturally Inspired. Scientifically Defined
INDUSTRY
Medical
STATUS
closed
OPEN TO
Public
Investment Highlights
Company Overview
Simultaneous human and veterinary development model
Delivers earlier returns and reduces risks for human development
Treating tumours & wounds with high-value, inter-related programmes
Human oncology & would healing pharmaceutical
Proprietary drug discovery platform EcoLogic™
Offer potential for long term growth targeting only the best biologically active molecules
Veterninary pharmaceuticals already in the market
Marketing veterinary drug STELFONTA in the US, Europe and Australia
QBiotics research and development program is based on compounds derived from the Australian tropical rainforest.
The product focus addresses unmet medical needs for humans and companion animals, with a concentration on the global health priority areas of cancer, specifically solid tumours, and chronic wound management.
QBiotics is an Australian life sciences company, inspired by nature to improve human and animal health.
Pursuing both monotherapy and combination therapy avenues in clinical trials to test efficacy and safety – results of these studies provided a clinically relevant and highly validated model for cancer in humans
Current Market Cap >A$500M
850,000 shares available
Team
Dr Peter Schmidt
Chief Operating Officer
Michael Wenzel
Chief Financial Officer
Mary Phipps
Chief Marketing Officer
Dr Richard Yocum
Chief Medical Officer
Roberta Bozzili
Chief Legal & Commercial Officer
Ebru Davidson
General Counsel
Dr Tracey Mynott
Business Development Manager
Dr Sam Yurdakul
Director of Prduct Development
Ask us a Question
Send us a message and we'll connect soon
Become a member
Become a member and elevate your experience with us!
Already have an account? Login